Filing Flows › Health Care › Ensysce Biosciences (ENSC)
Ensysce Biosciences (ENSC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Ensysce Biosciences (ENSC) Q2 2026 earnings results →
Q2 2026 Revenue down 15% year over year to $1.2M · 221¢ of every $1 of revenue lost · operating margin -221.3%
Ensysce Biosciences made $1.2M in Q2 2026 (-15% Y/Y). Operating margin -221.3%, net loss $2.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2M in Q2 2026, down 15% year over year and up 21% from the previous quarter.
Operating costs exceeded revenue by $2.6M, an operating margin of -221.3%. Total costs grew 20% against a revenue fall of 15%. The fastest-growing cost line was Research & development (+29%). The quarter ended with a net loss of $2.6M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $7K of depreciation and $2K of share-based compensation. Working capital and other items added $600K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $1.2M | -15% | -221.3% | −$2.6M | −$2.0M |
| Q1 2026 | 10-Q | May 15, 2026 | $961K | -27% | -370.7% | −$3.6M | −$3.5M |
| Q4 2025 | 10-K | Mar 30, 2026 | $1.9M | +44% | -147.8% | −$2.8M | −$1.5M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $493K | -86% | -758.7% | −$3.7M | −$1.9M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $1.4M | +654% | -127.6% | −$1.7M | −$2.7M |
| Q1 2025 | 10-Q | May 13, 2025 | $1.3M | +332% | -149.1% | −$1.9M | −$1.7M |
| Q4 2024 | 10-K | Mar 10, 2025 | $1.3M | +153% | -274.3% | −$3.6M | −$764K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Ensysce Biosciences
We were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from PharmacoFore, Inc. to Signature Therapeutics Inc. (“ Signature ”). In December 2015, Signature merged with and into Ensysce Biosciences, Inc. (“ Former Ensysce ”). In June 2021, Former Ensysce merged with and into Leisure Acquisition Corporation (“ LACQ ”). As part of the transaction, LACQ changed its name to “Ensysce Biosciences, Inc.” The mailing address of our principal executive office is 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Our corporate telephone number is (858) 263-4196. Our website address is www.ensysce.com. Information contained on our website, or connected thereto, does not constitute part of, and is not incorporated by reference into, this Annual Report on Form 10-K.
In its own words, from its 10-K, filed Mar 30, 2026.
Ensysce Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -15% against the peers' median +7%. Operating margin: -221.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ENSC Ensysce Biosciences | Q2 2026 | $1.2M | -15% | -221.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Ensysce Biosciences 10-Q on SEC EDGAR · CIK 1716947 · Pharmaceutical Preparations
13F: who owns ENSC and who is buying
More on ENSC
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results